Showing results (561-570 of 727) with videos related to
Sort By:
Pageof 73
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 6, 2026
Presenting features and outcomes to standard systemic therapies in patients with MTAP-deleted advanced non-small cell lung cancerJulian Huang, Mihaela Aldea, Kathryn W Miller, et al.Cancer Research and Treatment|July 14, 2017
Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung CancerMakoto Nishio, Dong-Wan Kim, Yi-Long Wu, et al.Lung Cancer (Amsterdam, Netherlands)|November 30, 2024
Alectinib combined with cobimetinib in ALK-Rearranged lung Cancer: A phase IB studyIbiayi Dagogo-Jack, Alissa J Cooper, Bruce E Johnson, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 26, 2016
Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 SkippingRebecca S Heist, Lecia V Sequist, Darrell Borger, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 10, 2021
Outcomes According to ALK Status Determined by Central IHC or FISH in Patients with ALK-Positive NSCLC Enrolled in the Phase III ALEX StudyTony Mok, Solange Peters, D Ross Camidge, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2022
Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced ALK+ Non-small Cell Lung Cancer in the Global Phase III ALEX TrialRafal Dziadziuszko, Solange Peters, Tony Mok, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 18, 2020
Outcomes According to ALK Status Determined by Central Immunohistochemistry or Fluorescence In Situ Hybridization in Patients With ALK-Positive NSCLC Enrolled in the Phase 3 ALEX StudyTony Mok, Solange Peters, D Ross Camidge, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 18, 2014
Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinibRyohei Katayama, Luc Friboulet, Sumie Koike, et al.ESMO Open|December 13, 2021
Safety and activity of alectinib plus bevacizumab in patients with advanced ALK-rearranged non-small-cell lung cancer: a phase I/II studyJ J Lin, A Muzikansky, E Kennedy, et al.Clinical Oncology (Royal College of Radiologists (Great Britain))|July 8, 2026
Seizure Risk in Patients With Brain Metastases: Interim Analysis From a Prospective Observational Study. Is it Time to Review Driving Policy?J de Boisanger, J Konadu, A Tran, et al.Pageof 73